Navigation Links
Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated
Date:2/5/2008

rom the study and reported adverse events were generally mild and transient.

"This study is an important step forward in the clinical development of tezampanel. Our ability to safely deliver multiple doses of tezampanel means that we can now pursue virtually any indication that requires chronic dosing," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "There is an emerging appreciation of the pathological effects of increased AMPA and kainate receptor activation by glutamate. By blocking both receptors, tezampanel and its oral prodrug, NGX426, may represent a unique and effective approach to treat a variety of chronic pain as well as non-pain conditions."

Tezampanel is the first AMPA/kainate antagonist to be studied in clinical trials for chronic pain. Both tezampanel and NGX426 represent a novel, non-opiod, non-vascular and non-serotonergic approach to treating multiple chronic pain conditions. Tezampanel and NGX426 are antagonists of a subgroup of glutamate receptors referred to as AMPA and kainate. These receptors are found in areas of the central and peripheral nervous system that are important for the transmission of pain. For example, during a migraine attack, levels of glutamate increase and activate these receptors, facilitating the transmission of pain impulses. Tezampanel, by blocking the binding of glutamate to these receptors, is believed to inhibit the transmission of pain signals that lead to migraine headaches. The blockade of similar receptors in other regions of the brain or spinal cord has been shown in animal models to attenuate pathophysiological processes such as the muscle spasticity and rigidity that occurs following stroke and spinal cord injury, or that may be associated with multiple sclerosis.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of small mo
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
4. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
5. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
11. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- TechniScan, Inc. (OTC Bulletin Board: ... company engaged in the development and commercialization of ... that Joe Pepper, PhD, has been appointed to ... Chairman Ken Hungerford commented, "Joe has extensive experience ... GE OEC Medical and U-Systems, both of whom ...
(Date:12/16/2009)... Inc., a new clinical stage company developing innovative ... on its novel GFPA NMDA receptor modulators, today ... meeting showed that its lead compound GLYX-13 demonstrated ... of the CNS-related side effects seen with other ... also showed that GLYX-13,s antidepressant effects were evident ...
(Date:12/16/2009)... SAN DIEGO, Dec. 16 Optimer Pharmaceuticals, ... present at the 28th Annual J.P. Morgan Healthcare ... San Francisco on Wednesday, January 13, 2010. Michael ... will present at 2:30 p.m. Pacific Time (5:30 ... ,, A live audio webcast of this presentation ...
Breaking Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 6628 1Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 6628 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 6628 3China Biologic Products Approved to List on NASDAQ 6626 1China Biologic Products Approved to List on NASDAQ 6626 2China Biologic Products Approved to List on NASDAQ 6626 3ADVENTRX Pharmaceuticals Reports Additional Pre Clinical Data for ANX 514 6624 1ADVENTRX Pharmaceuticals Reports Additional Pre Clinical Data for ANX 514 6624 2ADVENTRX Pharmaceuticals Reports Additional Pre Clinical Data for ANX 514 6624 3
... Va., Oct. 18 CEL-SCI CORPORATION,(Amex: CVM ... Geert,Kersten, is a featured presenter at the International ... Maryland. Mr. Kersten will present on the "New ... 3:15 p.m. (Eastern Daylight,Time). In April 2007, ...
... Oct. 18 Access Pharmaceuticals, Inc.,(OTC Bulletin ... will be,presenting clinical and preclinical data on ... symposium of the American Association for,Cancer Research ... for Research and Treatment of Cancer (EORTC) ...
Other Medicine Technology:CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase 2Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 2
(Date:12/16/2009)... 16 For ages, people from around the ... properties. Its soothing waters have a reputation that dates ... involvement with miracles. Now, with the introduction of two ... can enjoy the legendary benefits of Dead Sea salt ... lines contain all-natural Dead Sea salt and essential oils ...
(Date:12/16/2009)... More Americans have myopia now than in the ,70s, ... Myopia (nearsightedness) is more common in the United States ... National Eye Institute study shows. , Researchers compared National ... and white participants from 1971 to 1972 and from ... The participants were 12 to 54 years old. , ...
(Date:12/16/2009)... trial bottle sample with purchase of 90-count bottle. , ... ... announces a special free offer for a “Free 21-Count ... Formula , with the purchase of a 90-count bottle. Distributed ... in FDA approved facilities and blends the 6 most important medicinal ...
(Date:12/16/2009)... Request A Test, Ltd. is proud to announce being presented with ... Weatherhead 100 showcases the fastest growing companies in Northeast Ohio and ... to succeed. , ... (PRWEB) December ... being presented with the Weatherhead 100 Upstart Award on December 3, ...
(Date:12/16/2009)... perfect gift to give that special woman who has everything? ... Mary Schook introduces exceptional beauty products online while educating the public ... ... (PRWEB) December 16, 2009 -- The holidays are rapidly approaching ... woman who has everything? Why stem cells, of course!, , , ...
Breaking Medicine News(10 mins):Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 2Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 4Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2
... CUR, QUEBEC CITY, June 3 /PRNewswire-FirstCall/ - Two ... the detection of prostate cancer,and GCC for the staging ... part of the growing trend to molecular diagnostics., ... the 34th,Annual International Clinical Ligand Assay Society Meeting, held ...
... Trainers For Peak ... Performance, LOS ANGELES, June 2 ... Cher, now the,Pussycat Dolls are working out with Bally. On the verge of ... for,their hot new single "When I Grow Up," the Pussycat Dolls are getting ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... today that it has acquired,Physicians Home Health Care ... $12 million in cash. The transaction will be ... established by a group of physicians in 1984, ...
... of autoantibody-secreting cells, have emerged as promising new ... (RA). In particular, B cell depletion with ... RA patients resistant to standard disease-modifying antirheumatic drugs ... In large trials, about half of these ...
... 2 The International Rett Syndrome,Foundation announced today ... Chief Scientific Officer, beginning July 1. Dr. Horton ... of Rett,Clinics, a series of clinics throughout the ... addition, Dr. Horton will,assist the IRSF Board of ...
... There is still time to enter,the American Academy ... to boys and girls in two groups, grades 3-5 ... will be invited to attend,the 2008 AAP National Conference ... winners will receive $500 and up to $1,000 for ...
Other Medicine News:Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 2Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 3Health News:Pussycat Dolls Shape Up With Bally Total Fitness 2Health News:Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider 2Health News:Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider 3Health News:Study of anti-CD20 therapy effective B cell depletion 2Health News:The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer 2
US Autoflow Single Chamber Stackable Water-Jacketed CO2 Inc.w/ Humidity Display and Control...
3.0% Tryptone, 2.0% Yeast Extract, 1.0% MOPS free acid, 2.0% Glucose....
0.3% Beef extract, 0.5% Peptone, 0.5 % Lactose....
... The user-friendly Eppendorf Thermomixer R offers ... that require shaking, heating, and cooling. ... expanded its application and temperature control ... each accommodate 24 micro test tubes, ...
Medicine Products: